世界のアテローム性動脈硬化症薬剤市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Atherosclerosis Drugs Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-3866 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、97ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、アテローム性動脈硬化症薬剤の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（コルチコステロイド、PDE4阻害剤、生物製剤、皮膚バリアエモリエント、CNI免疫抑制剤、その他）、用途別市場規模（病院、診療所、小売薬局、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・アテローム性動脈硬化症薬剤の市場動向 ・企業の競争状況、市場シェア ・アテローム性動脈硬化症薬剤の種類別市場規模と予測2016-2027（コルチコステロイド、PDE4阻害剤、生物製剤、皮膚バリアエモリエント、CNI免疫抑制剤、その他） ・アテローム性動脈硬化症薬剤の用途別市場規模と予測2016-2027（病院、診療所、小売薬局、その他） ・アテローム性動脈硬化症薬剤の北米市場規模2016-2027（アメリカ、カナダ） ・アテローム性動脈硬化症薬剤の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・アテローム性動脈硬化症薬剤のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・アテローム性動脈硬化症薬剤の中南米市場規模2016-2027（メキシコ、ブラジル） ・アテローム性動脈硬化症薬剤の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（GlaxoSmithKline、Sanofi、F. Hoffmann-L a Roche、Bayer、Novartis、Merck、Janssen Pharmaceutical、Amgen、Pfizer） ・結論

Market Analysis and Insights: Global Atherosclerosis Drugs Market
The global Atherosclerosis Drugs market size is projected to reach US$ 43670 million by 2027, from US$ 38400 million in 2020, at a CAGR of 1.4% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Atherosclerosis Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Atherosclerosis Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Atherosclerosis Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Atherosclerosis Drugs market.

Global Atherosclerosis Drugs Scope and Market Size
Atherosclerosis Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Atherosclerosis Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Corticosteroids
PDE4 Inhibitors
Biologics
Skin Barrier Emollients
CNI Immunosuppressants
Others

Segment by Application
Hospital
Clinic
Retail Pharmacies
Other

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
GlaxoSmithKline
Sanofi
F. Hoffmann-L a Roche
Bayer
Novartis
Merck
Janssen Pharmaceutical
Amgen
Pfizer

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Atherosclerosis Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Corticosteroids
1.2.3 PDE4 Inhibitors
1.2.4 Biologics
1.2.5 Skin Barrier Emollients
1.2.6 CNI Immunosuppressants
1.2.7 Others
1.3 Market by Application
1.3.1 Global Atherosclerosis Drugs Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Retail Pharmacies
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Atherosclerosis Drugs Market Perspective (2016-2027)
2.2 Atherosclerosis Drugs Growth Trends by Regions
2.2.1 Atherosclerosis Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Atherosclerosis Drugs Historic Market Share by Regions (2016-2021)
2.2.3 Atherosclerosis Drugs Forecasted Market Size by Regions (2022-2027)
2.3 Atherosclerosis Drugs Industry Dynamic
2.3.1 Atherosclerosis Drugs Market Trends
2.3.2 Atherosclerosis Drugs Market Drivers
2.3.3 Atherosclerosis Drugs Market Challenges
2.3.4 Atherosclerosis Drugs Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Atherosclerosis Drugs Players by Revenue
3.1.1 Global Top Atherosclerosis Drugs Players by Revenue (2016-2021)
3.1.2 Global Atherosclerosis Drugs Revenue Market Share by Players (2016-2021)
3.2 Global Atherosclerosis Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Atherosclerosis Drugs Revenue
3.4 Global Atherosclerosis Drugs Market Concentration Ratio
3.4.1 Global Atherosclerosis Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Atherosclerosis Drugs Revenue in 2020
3.5 Atherosclerosis Drugs Key Players Head office and Area Served
3.6 Key Players Atherosclerosis Drugs Product Solution and Service
3.7 Date of Enter into Atherosclerosis Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Atherosclerosis Drugs Breakdown Data by Type
4.1 Global Atherosclerosis Drugs Historic Market Size by Type (2016-2021)
4.2 Global Atherosclerosis Drugs Forecasted Market Size by Type (2022-2027)

5 Atherosclerosis Drugs Breakdown Data by Application
5.1 Global Atherosclerosis Drugs Historic Market Size by Application (2016-2021)
5.2 Global Atherosclerosis Drugs Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Atherosclerosis Drugs Market Size (2016-2027)
6.2 North America Atherosclerosis Drugs Market Size by Type
6.2.1 North America Atherosclerosis Drugs Market Size by Type (2016-2021)
6.2.2 North America Atherosclerosis Drugs Market Size by Type (2022-2027)
6.2.3 North America Atherosclerosis Drugs Market Size by Type (2016-2027)
6.3 North America Atherosclerosis Drugs Market Size by Application
6.3.1 North America Atherosclerosis Drugs Market Size by Application (2016-2021)
6.3.2 North America Atherosclerosis Drugs Market Size by Application (2022-2027)
6.3.3 North America Atherosclerosis Drugs Market Size by Application (2016-2027)
6.4 North America Atherosclerosis Drugs Market Size by Country
6.4.1 North America Atherosclerosis Drugs Market Size by Country (2016-2021)
6.4.2 North America Atherosclerosis Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Atherosclerosis Drugs Market Size (2016-2027)
7.2 Europe Atherosclerosis Drugs Market Size by Type
7.2.1 Europe Atherosclerosis Drugs Market Size by Type (2016-2021)
7.2.2 Europe Atherosclerosis Drugs Market Size by Type (2022-2027)
7.2.3 Europe Atherosclerosis Drugs Market Size by Type (2016-2027)
7.3 Europe Atherosclerosis Drugs Market Size by Application
7.3.1 Europe Atherosclerosis Drugs Market Size by Application (2016-2021)
7.3.2 Europe Atherosclerosis Drugs Market Size by Application (2022-2027)
7.3.3 Europe Atherosclerosis Drugs Market Size by Application (2016-2027)
7.4 Europe Atherosclerosis Drugs Market Size by Country
7.4.1 Europe Atherosclerosis Drugs Market Size by Country (2016-2021)
7.4.2 Europe Atherosclerosis Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Atherosclerosis Drugs Market Size (2016-2027)
8.2 Asia-Pacific Atherosclerosis Drugs Market Size by Type
8.2.1 Asia-Pacific Atherosclerosis Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Atherosclerosis Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Atherosclerosis Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific Atherosclerosis Drugs Market Size by Application
8.3.1 Asia-Pacific Atherosclerosis Drugs Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Atherosclerosis Drugs Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Atherosclerosis Drugs Market Size by Application (2016-2027)
8.4 Asia-Pacific Atherosclerosis Drugs Market Size by Region
8.4.1 Asia-Pacific Atherosclerosis Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Atherosclerosis Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Atherosclerosis Drugs Market Size (2016-2027)
9.2 Latin America Atherosclerosis Drugs Market Size by Type
9.2.1 Latin America Atherosclerosis Drugs Market Size by Type (2016-2021)
9.2.2 Latin America Atherosclerosis Drugs Market Size by Type (2022-2027)
9.2.3 Latin America Atherosclerosis Drugs Market Size by Type (2016-2027)
9.3 Latin America Atherosclerosis Drugs Market Size by Application
9.3.1 Latin America Atherosclerosis Drugs Market Size by Application (2016-2021)
9.3.2 Latin America Atherosclerosis Drugs Market Size by Application (2022-2027)
9.3.3 Latin America Atherosclerosis Drugs Market Size by Application (2016-2027)
9.4 Latin America Atherosclerosis Drugs Market Size by Country
9.4.1 Latin America Atherosclerosis Drugs Market Size by Country (2016-2021)
9.4.2 Latin America Atherosclerosis Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Atherosclerosis Drugs Market Size (2016-2027)
10.2 Middle East & Africa Atherosclerosis Drugs Market Size by Type
10.2.1 Middle East & Africa Atherosclerosis Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Atherosclerosis Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Atherosclerosis Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa Atherosclerosis Drugs Market Size by Application
10.3.1 Middle East & Africa Atherosclerosis Drugs Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Atherosclerosis Drugs Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Atherosclerosis Drugs Market Size by Application (2016-2027)
10.4 Middle East & Africa Atherosclerosis Drugs Market Size by Country
10.4.1 Middle East & Africa Atherosclerosis Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Atherosclerosis Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 GlaxoSmithKline
11.1.1 GlaxoSmithKline Company Details
11.1.2 GlaxoSmithKline Business Overview
11.1.3 GlaxoSmithKline Atherosclerosis Drugs Introduction
11.1.4 GlaxoSmithKline Revenue in Atherosclerosis Drugs Business (2016-2021)
11.1.5 GlaxoSmithKline Recent Development
11.2 Sanofi
11.2.1 Sanofi Company Details
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Atherosclerosis Drugs Introduction
11.2.4 Sanofi Revenue in Atherosclerosis Drugs Business (2016-2021)
11.2.5 Sanofi Recent Development
11.3 F. Hoffmann-L a Roche
11.3.1 F. Hoffmann-L a Roche Company Details
11.3.2 F. Hoffmann-L a Roche Business Overview
11.3.3 F. Hoffmann-L a Roche Atherosclerosis Drugs Introduction
11.3.4 F. Hoffmann-L a Roche Revenue in Atherosclerosis Drugs Business (2016-2021)
11.3.5 F. Hoffmann-L a Roche Recent Development
11.4 Bayer
11.4.1 Bayer Company Details
11.4.2 Bayer Business Overview
11.4.3 Bayer Atherosclerosis Drugs Introduction
11.4.4 Bayer Revenue in Atherosclerosis Drugs Business (2016-2021)
11.4.5 Bayer Recent Development
11.5 Novartis
11.5.1 Novartis Company Details
11.5.2 Novartis Business Overview
11.5.3 Novartis Atherosclerosis Drugs Introduction
11.5.4 Novartis Revenue in Atherosclerosis Drugs Business (2016-2021)
11.5.5 Novartis Recent Development
11.6 Merck
11.6.1 Merck Company Details
11.6.2 Merck Business Overview
11.6.3 Merck Atherosclerosis Drugs Introduction
11.6.4 Merck Revenue in Atherosclerosis Drugs Business (2016-2021)
11.6.5 Merck Recent Development
11.7 Janssen Pharmaceutical
11.7.1 Janssen Pharmaceutical Company Details
11.7.2 Janssen Pharmaceutical Business Overview
11.7.3 Janssen Pharmaceutical Atherosclerosis Drugs Introduction
11.7.4 Janssen Pharmaceutical Revenue in Atherosclerosis Drugs Business (2016-2021)
11.7.5 Janssen Pharmaceutical Recent Development
11.8 Amgen
11.8.1 Amgen Company Details
11.8.2 Amgen Business Overview
11.8.3 Amgen Atherosclerosis Drugs Introduction
11.8.4 Amgen Revenue in Atherosclerosis Drugs Business (2016-2021)
11.8.5 Amgen Recent Development
11.9 Pfizer
11.9.1 Pfizer Company Details
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Atherosclerosis Drugs Introduction
11.9.4 Pfizer Revenue in Atherosclerosis Drugs Business (2016-2021)
11.9.5 Pfizer Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Atherosclerosis Drugs Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Corticosteroids
Table 3. Key Players of PDE4 Inhibitors
Table 4. Key Players of Biologics
Table 5. Key Players of Skin Barrier Emollients
Table 6. Key Players of CNI Immunosuppressants
Table 7. Key Players of Others
Table 8. Global Atherosclerosis Drugs Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Atherosclerosis Drugs Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 10. Global Atherosclerosis Drugs Market Size by Regions (2016-2021) & (US$ Million)
Table 11. Global Atherosclerosis Drugs Market Share by Regions (2016-2021)
Table 12. Global Atherosclerosis Drugs Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 13. Global Atherosclerosis Drugs Market Share by Regions (2022-2027)
Table 14. Atherosclerosis Drugs Market Trends
Table 15. Atherosclerosis Drugs Market Drivers
Table 16. Atherosclerosis Drugs Market Challenges
Table 17. Atherosclerosis Drugs Market Restraints
Table 18. Global Atherosclerosis Drugs Revenue by Players (2016-2021) & (US$ Million)
Table 19. Global Atherosclerosis Drugs Market Share by Players (2016-2021)
Table 20. Global Top Atherosclerosis Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Atherosclerosis Drugs as of 2020)
Table 21. Ranking of Global Top Atherosclerosis Drugs Companies by Revenue (US$ Million) in 2020
Table 22. Global 5 Largest Players Market Share by Atherosclerosis Drugs Revenue (CR5 and HHI) & (2016-2021)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Atherosclerosis Drugs Product Solution and Service
Table 25. Date of Enter into Atherosclerosis Drugs Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Atherosclerosis Drugs Market Size by Type (2016-2021) (US$ Million)
Table 28. Global Atherosclerosis Drugs Revenue Market Share by Type (2016-2021)
Table 29. Global Atherosclerosis Drugs Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 30. Global Atherosclerosis Drugs Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 31. Global Atherosclerosis Drugs Market Size Share by Application (2016-2021) & (US$ Million)
Table 32. Global Atherosclerosis Drugs Revenue Market Share by Application (2016-2021)
Table 33. Global Atherosclerosis Drugs Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 34. Global Atherosclerosis Drugs Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 35. North America Atherosclerosis Drugs Market Size by Type (2016-2021) (US$ Million)
Table 36. North America Atherosclerosis Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 37. North America Atherosclerosis Drugs Market Size by Application (2016-2021) (US$ Million)
Table 38. North America Atherosclerosis Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 39. North America Atherosclerosis Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 40. North America Atherosclerosis Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 41. Europe Atherosclerosis Drugs Market Size by Type (2016-2021) (US$ Million)
Table 42. Europe Atherosclerosis Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 43. Europe Atherosclerosis Drugs Market Size by Application (2016-2021) (US$ Million)
Table 44. Europe Atherosclerosis Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 45. Europe Atherosclerosis Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 46. Europe Atherosclerosis Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Atherosclerosis Drugs Market Size by Type (2016-2021) (US$ Million)
Table 48. Asia-Pacific Atherosclerosis Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Atherosclerosis Drugs Market Size by Application (2016-2021) (US$ Million)
Table 50. Asia-Pacific Atherosclerosis Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 51. Asia-Pacific Atherosclerosis Drugs Market Size by Region (2016-2021) & (US$ Million)
Table 52. Asia-Pacific Atherosclerosis Drugs Market Size by Region (2022-2027) & (US$ Million)
Table 53. Latin America Atherosclerosis Drugs Market Size by Type (2016-2021) (US$ Million)
Table 54. Latin America Atherosclerosis Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 55. Latin America Atherosclerosis Drugs Market Size by Application (2016-2021) (US$ Million)
Table 56. Latin America Atherosclerosis Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 57. Latin America Atherosclerosis Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 58. Latin America Atherosclerosis Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Atherosclerosis Drugs Market Size by Type (2016-2021) (US$ Million)
Table 60. Middle East & Africa Atherosclerosis Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Atherosclerosis Drugs Market Size by Application (2016-2021) (US$ Million)
Table 62. Middle East & Africa Atherosclerosis Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 63. Middle East & Africa Atherosclerosis Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 64. Middle East & Africa Atherosclerosis Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 65. GlaxoSmithKline Company Details
Table 66. GlaxoSmithKline Business Overview
Table 67. GlaxoSmithKline Atherosclerosis Drugs Product
Table 68. GlaxoSmithKline Revenue in Atherosclerosis Drugs Business (2016-2021) & (US$ Million)
Table 69. GlaxoSmithKline Recent Development
Table 70. Sanofi Company Details
Table 71. Sanofi Business Overview
Table 72. Sanofi Atherosclerosis Drugs Product
Table 73. Sanofi Revenue in Atherosclerosis Drugs Business (2016-2021) & (US$ Million)
Table 74. Sanofi Recent Development
Table 75. F. Hoffmann-L a Roche Company Details
Table 76. F. Hoffmann-L a Roche Business Overview
Table 77. F. Hoffmann-L a Roche Atherosclerosis Drugs Product
Table 78. F. Hoffmann-L a Roche Revenue in Atherosclerosis Drugs Business (2016-2021) & (US$ Million)
Table 79. F. Hoffmann-L a Roche Recent Development
Table 80. Bayer Company Details
Table 81. Bayer Business Overview
Table 82. Bayer Atherosclerosis Drugs Product
Table 83. Bayer Revenue in Atherosclerosis Drugs Business (2016-2021) & (US$ Million)
Table 84. Bayer Recent Development
Table 85. Novartis Company Details
Table 86. Novartis Business Overview
Table 87. Novartis Atherosclerosis Drugs Product
Table 88. Novartis Revenue in Atherosclerosis Drugs Business (2016-2021) & (US$ Million)
Table 89. Novartis Recent Development
Table 90. Merck Company Details
Table 91. Merck Business Overview
Table 92. Merck Atherosclerosis Drugs Product
Table 93. Merck Revenue in Atherosclerosis Drugs Business (2016-2021) & (US$ Million)
Table 94. Merck Recent Development
Table 95. Janssen Pharmaceutical Company Details
Table 96. Janssen Pharmaceutical Business Overview
Table 97. Janssen Pharmaceutical Atherosclerosis Drugs Product
Table 98. Janssen Pharmaceutical Revenue in Atherosclerosis Drugs Business (2016-2021) & (US$ Million)
Table 99. Janssen Pharmaceutical Recent Development
Table 100. Amgen Company Details
Table 101. Amgen Business Overview
Table 102. Amgen Revenue in Atherosclerosis Drugs Business (2016-2021) & (US$ Million)
Table 103. Amgen Recent Development
Table 104. Pfizer Company Details
Table 105. Pfizer Business Overview
Table 106. Pfizer Atherosclerosis Drugs Product
Table 107. Pfizer Revenue in Atherosclerosis Drugs Business (2016-2021) & (US$ Million)
Table 108. Pfizer Recent Development
Table 109. Research Programs/Design for This Report
Table 110. Key Data Information from Secondary Sources
Table 111. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Atherosclerosis Drugs Market Share by Type: 2020 VS 2027
Figure 2. Corticosteroids Features
Figure 3. PDE4 Inhibitors Features
Figure 4. Biologics Features
Figure 5. Skin Barrier Emollients Features
Figure 6. CNI Immunosuppressants Features
Figure 7. Others Features
Figure 8. Global Atherosclerosis Drugs Market Share by Application: 2020 VS 2027
Figure 9. Hospital Case Studies
Figure 10. Clinic Case Studies
Figure 11. Retail Pharmacies Case Studies
Figure 12. Other Case Studies
Figure 13. Atherosclerosis Drugs Report Years Considered
Figure 14. Global Atherosclerosis Drugs Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 15. Global Atherosclerosis Drugs Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 16. Global Atherosclerosis Drugs Market Share by Regions: 2020 VS 2027
Figure 17. Global Atherosclerosis Drugs Market Share by Regions (2022-2027)
Figure 18. Global Atherosclerosis Drugs Market Share by Players in 2020
Figure 19. Global Top Atherosclerosis Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Atherosclerosis Drugs as of 2020
Figure 20. The Top 10 and 5 Players Market Share by Atherosclerosis Drugs Revenue in 2020
Figure 21. Global Atherosclerosis Drugs Revenue Market Share by Type (2016-2021)
Figure 22. Global Atherosclerosis Drugs Revenue Market Share by Type (2022-2027)
Figure 23. North America Atherosclerosis Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. North America Atherosclerosis Drugs Market Share by Type (2016-2027)
Figure 25. North America Atherosclerosis Drugs Market Share by Application (2016-2027)
Figure 26. North America Atherosclerosis Drugs Market Share by Country (2016-2027)
Figure 27. United States Atherosclerosis Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Canada Atherosclerosis Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Atherosclerosis Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Europe Atherosclerosis Drugs Market Share by Type (2016-2027)
Figure 31. Europe Atherosclerosis Drugs Market Share by Application (2016-2027)
Figure 32. Europe Atherosclerosis Drugs Market Share by Country (2016-2027)
Figure 33. Germany Atherosclerosis Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. France Atherosclerosis Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. U.K. Atherosclerosis Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Italy Atherosclerosis Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Russia Atherosclerosis Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Nordic Atherosclerosis Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Atherosclerosis Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Asia-Pacific Atherosclerosis Drugs Market Share by Type (2016-2027)
Figure 41. Asia-Pacific Atherosclerosis Drugs Market Share by Application (2016-2027)
Figure 42. Asia-Pacific Atherosclerosis Drugs Market Share by Region (2016-2027)
Figure 43. China Atherosclerosis Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Japan Atherosclerosis Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. South Korea Atherosclerosis Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Southeast Asia Atherosclerosis Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. India Atherosclerosis Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Australia Atherosclerosis Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Atherosclerosis Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Latin America Atherosclerosis Drugs Market Share by Type (2016-2027)
Figure 51. Latin America Atherosclerosis Drugs Market Share by Application (2016-2027)
Figure 52. Latin America Atherosclerosis Drugs Market Share by Country (2016-2027)
Figure 53. Mexico Atherosclerosis Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Brazil Atherosclerosis Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Atherosclerosis Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Middle East & Africa Atherosclerosis Drugs Market Share by Type (2016-2027)
Figure 57. Middle East & Africa Atherosclerosis Drugs Market Share by Application (2016-2027)
Figure 58. Middle East & Africa Atherosclerosis Drugs Market Share by Country (2016-2027)
Figure 59. Turkey Atherosclerosis Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Saudi Arabia Atherosclerosis Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. UAE Atherosclerosis Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 62. GlaxoSmithKline Revenue Growth Rate in Atherosclerosis Drugs Business (2016-2021)
Figure 63. Sanofi Revenue Growth Rate in Atherosclerosis Drugs Business (2016-2021)
Figure 64. F. Hoffmann-L a Roche Revenue Growth Rate in Atherosclerosis Drugs Business (2016-2021)
Figure 65. Bayer Revenue Growth Rate in Atherosclerosis Drugs Business (2016-2021)
Figure 66. Novartis Revenue Growth Rate in Atherosclerosis Drugs Business (2016-2021)
Figure 67. Merck Revenue Growth Rate in Atherosclerosis Drugs Business (2016-2021)
Figure 68. Janssen Pharmaceutical Revenue Growth Rate in Atherosclerosis Drugs Business (2016-2021)
Figure 69. Amgen Revenue Growth Rate in Atherosclerosis Drugs Business (2016-2021)
Figure 70. Pfizer Revenue Growth Rate in Atherosclerosis Drugs Business (2016-2021)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed

---